Regulatory Science As Culture: Contested Two-dimensional Values at the US FDA

Science as Culture

Volumn 11, Issue 3, 2002, Pages 309-335

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; TRIAZOLAM;

ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; ELI LILLY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE AND PUBLIC HEALTH; HUMAN; LEGAL APPROACH; LEGAL ASPECT; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PERSONNEL; RISK ASSESSMENT; UNITED STATES; UPJOHN COMPANY;

ELI LILLY; HEALTH CARE AND PUBLIC HEALTH; LEGAL APPROACH; UPJOHN COMPANY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS; DRUG APPROVAL; DRUG INDUSTRY; GOVERNMENT REGULATION; HUMANS; MODELS, ORGANIZATIONAL; RESEARCH PERSONNEL; RISK ASSESSMENT; TRIAZOLAM; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0348054731     PISSN: 09505431     EISSN: 14701189     Source Type: Journal    
DOI: 10.1080/0950543022000005069     Document Type: Article

References (64)

1. Abraham, J., 1993. 'Scientific standards and institutional interests:carcinogenic risk assessment of benoxaprofen in the UK and US'. Social Studies of Science, 23:387–444.
2. Abraham, J., 1995. Science, Politics and the Pharmaceutical Industry:Controversy and Bias in Drug Regulation, London/New York:UCL/St Martins Press.
3. Abraham, J., and Lewis, G., 2000. Regulating Medicines in Europe:Competition, Expertise and Public Health, London:Routledge.
4. Abraham, J., and Millstone, E., 1989. 'Food additive controls:some international comparisons'. Food Policy, 14:43–57.
5. Allison, P.D., and Long, J.S., 1990. 'Departmental effects on scientific productivity'. American Sociological Review, 55:469–478.
6. Anon. 1988a. 'Top US companies in 1987'. Scrip, 1306:2
7. Anon. 1988b. 'Xanax and Halcion boost Upjohn's sales'. Scrip, 1306:12
8. Asscher, W., 1991. “'Dear Doctor'”. In Letter from Chairman of the UK Committee on the Safety of Medicines, London:Department of Health.
9. Barnes, B., 1971. 'Making out in industrial research'. Science Studies, 1:157–175.
10. Barnes, B., 1977. Interests and the Growth of Knowledge, London:Routledge and Kegan Paul.
11. Barnes, B., 1982. T.S. Kuhn and Social Science, London:Macmillan.
12. Bloor, D., 1992. “'Left and right Wittgensteinians'”. In Science as Practice and Culture, Edited by:Pickering, A., Chicago and London:University of Chicago Press.
13. Blume, S.S., 1974. Toward a Political Sociology of Science, New York:The Free Press.
14. Bodewitz, H., Buurma, H., and de Vries, G., 1987. “'Regulatory science and the social management of trust in medicine'”. In The Social Construction of Technological Systems, Edited by:Bijker, W.E., Hughes, T., and Pinch, T., 243–259. Cambridge, MA:MIT Press.
15. Brickman, R., Jasanoff, S., and Ilgen, T., 1985. Controlling Chemicals:The Politics of Regulation in Europe and the United States, Ithaca, NY:Cornell University Press.
16. CBS. 1991. 60 Minutes. Columbia Broadcasting System, 15 December
17. Collins, H.M., 1985. Changing Order:Replication and Induction in Scientific Practice, London:Sage.
18. Cotgrove, S., and Box, S., 1970. Science, Industry and Society, London:Alien and Unwin.
19. Daemmrich, A., and Krucken, G., 2000. 'Risk versus risk:decision-making dilemmas of drug regulation in the US and Germany'. Science as Culture, 9:505–534.
20. Ehrlich, C., 1988a. “'Halcion nightmare:the frightening story about America's favourite sleeping pill'”. 60–67. 119California
21. Ehrlich, C., 1988b. “'Halcion:prescription for trouble'”. 74–77. California
22. Ellis, N.D., 1969. “'The occupation of science'”. In Sociology of Science, Edited by:Barnes, B., 188–205. Harmondsworth, England:Penguin Books.
23. Epstein, S., 1995. 'The construction of lay expertise:AIDS activism and the forging of credibility in the reform of clinical trials'. Science Technology & Human Values, 20:408–437.
24. Food and Drug Administration (FDA). 1988a. 'Planned Upjohn announcement to discontinue manufacture of 0.5 mg dose of Halcion'. Internal Memorandum of Telecon from Paul Leber to Robert Temple, Director of Drug Research and Review
25. Food and Drug Administration (FDA). 1988b. 'Halcion'. Internal Memorandumfrom Charles Anello to Paul Leber
26. Food and Drug Administration (FDA). 1989. “'Interpreting post-marketing surveillance information on Halcion'”. In Letter from Paul Leber to members of Psychopharmacological Drugs Advisory Committee
27. Fries, S.D., 1984. 'The ideology of science during the Nixon years:1970-76'. Social Studies of Science, 14:323–341.
28. Gillespie, B., Eva, P., and Johnston, R., 1979. 'Carcinogenic risk assessment in the United States and Great Britain:the case of aldrin/deildrin'. Social Studies of Science, 9:265–301.
29. Grabowski, G., Vernon, J., and Thomas, L., 1978. 'Estimating the effects of regulation on innovation:an international comparative analysis of the pharmaceutical industry'. Journal of Law and Economics, 21:133–163.
30. Halpern, S.A., 1992. 'Dynamics of professional control:internal coalitions and cross-professional boundaries'. American Journal of Sociology, 97:994–1021.
31. Hensley, MJ. 1981. Investigations of Eli Lilly (Benoxaprofen Adverse Effects), Preliminary Report to Chief of Clinical Investigations Branch Division of Scientific Investigations, Food and Drug Administration.
32. Hensley, MJ. 1983. Deposition in Clarence Borom vs Eli Lilly and Company, District Court for the Middle District of Georgia, Columbus Division.
33. Irwin, A., 1985. Risk and the Control of Technology:Public Policies for Road Traffic Safety in Britain and the United States, Manchester, England:Manchester University Press.
34. Irwin, A., Rothstein, H., Yearley, S., and McCarthy, E., 1997. 'Regulatory science--towards a sociological framework'. Futures, 29:17–31.
35. Jasanoff, S., 1990. The Fifth Branch:Science Advisers as Policymakers, Cambridge, MA:Harvard University Press.
36. Kaitin, K.J., Mattison, N., Northington, F.K., and Lasagna, L., 1989. 'The drug lag:an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987'. Clinical Pharmacology and Therapeutics, 46:121–138.
37. Kales, A., 1983. 'Early morning insomnia with rapidly eliminated benzodi- azepines'. Science, 220:95–97.
38. Kelman, S., 1981. Regulating Sweden, Regulating America:A Comparative Study of Occupational Safety and Health Policy, Cambridge, MA:MIT Press.
39. Krohn, R.G., 1971. The Social Shaping of Science, Westport, CT:Greenwood Publishing.
40. Kuhn, T.S., 1962. The Structure of Scientific Revolutions, Chicago:University of Chicago Press.
41. Leventhal, R.G., 1983. Deposition in Clarence Borom vs Eli Lilly and Company, District Court for the Middle District of Georgia, Columbus Division.
42. Long, J.S., and McGinnis, R., 1981. Organizational context and scientific productivity'. American Sociological Review, 46:422–442.
43. MacNeil-Lehrer News Hour. 1989. Halcion. Public Broadcasting Service, 1 September
44. Majone, G., 1996. Regulating Europe, London:Routledge.
45. Merton, R.K., 1942. “'The normative structure of science'”. In The Sociology of Science:Theoretical and Empirical Investigations, Edited by:Storer, N., 267–278. Chicago:University of Chicago Press.
46. Mitroff, I., 1994. 'Norms and counter-norms in a select group of the Apollo moon scientists'. American Sociological Review, 39:579–595.
47. Morgan, K., and Oswald, I., 1982. 'Anxiety caused by a short-life hypnotic'. British Medical Journal, 284:942
48. Mulkay, M., 1969. 'Some aspects of cultural growth in the natural sciences'. Social Research, 36:22–52.
49. Mulkay, M., 1976. 'Norms and ideology in science'. Social Science Information, 15:637–656.
50. Pickering, A., 1992. “'From science as knowledge to science as practice'”. In Science as Practice and Culture, Edited by:Pickering, A., Chicago and London:University of Chicago Press.
51. Pickering, A., and Stephanides, A., 1992. “'Constructing quaternions:on the analysis of conceptual practice'”. In Science as Practice and Culture, Edited by:Pickering, A., Chicago and London:University of Chicago Press.
52. Psychopharmacological Drugs Advisory Committee (PDAC). Transcript of PDAC Meeting on Halcion. Rockville, MD:FDA Headquarters.
53. Richards, E., 1991. Vitamin C and Cancer:Medicine or Politics?, London:Macmillan.
54. Royal Courts of Justice. 1994. Judgement Between the Upjohn Company and Upjohn Ltd and Professor Ian Oswald and Between Dr Royston Frederick Drucker and Professor Oswald and Between the Upjohn Company and Upjohn Ltd and the British Broadcasting Corporation and Tom Mangold, London:Beverley F. Nunnery. Before Mr Justice May
55. Shapin, S., 1979. “'The politics of observation:cerebral anatomy and social interests in the Edinburgh phrenology disputes'”. In On the Margins of Science:The Social Construction of Rejected Knowledge, Edited by:Wallis, R., Keele:University of Keele.
56. Soucek, M., 1994. Citizen's Petition:Halcion FDA Docket 94P-0336.CP1
57. Special Counsel to Congressional Review Panel on New Drug Regulation. 1977. Investigation of Allegations Relating to the Bureau of Drugs, Food and Drug Administration, Washington, DC:US GPO.
58. US Congress. 1974. Joint Hearings Before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Senate Committee on the Judiciary:Examination of the Pharmaceutical Industry Pt 7, Washington, DC:US GPO.
59. US Congress. 1982. Hearings of the Intergovernmental Relations and Human Resources Subcommittee of the House of Representatives Committee on Government Operations:The Regulation of New Drugs by the Food and Drug Administration, Washington, DC:US GPO.
60. Varma, R., 1999. 'Professional autonomy vs industrial control?'. Science as Culture, 8:23–45.
61. Wardell, W., 1976. 'Therapeutic implications of the drug lag'. Clinical Pharmacology and Therapeutics, 15:73–96.
62. Weinberg, A.M., 1985. 'Science and its limits:the regulator's dilemma'. Issues in Science and Technology, II Fall:67–76.
63. Wolfe, S.M., and Coley, C.M., 1980. Pills That Don't Work, New York:Farrar Straus Giroux.
64. Wyskowski, D.K., and Barash, D., 1991. 'Adverse behavioural reactions attributed to triazolam in the PDA's spontaneous reporting system'. Archives of Internal Medicine, 151:2003–2008.